Skip to main content

Zepbound Now Available Through Hims & Hers

Medically reviewed by Carmen Pope, BPharm. Last updated on April 2, 2025.

By I. Edwards HealthDay Reporter

WEDNESDAY, April 2, 2025 -- The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

The company said Tuesday it now provides access to Zepbound, a brand-name version of the drug tirzepatide, as well as to generic liraglutide.

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance, some patients may pay as little as $25, according to a report published by The Wall Street Journal.

Other medications for weight loss on the Hims & Hers platform include Ozempic and Wegovy, priced at $1,799 and $1,999 per month, respectively.

“We’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,” Hims & Hers said.

Lilly said it has no official connection with Hims & Hers.

Hims & Hers said it plans to keep expanding its offerings to help people find the treatment that works best for them.

“All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond,” Hims & Hers noted.

The company’s weight-loss business is growing fast. Hims & Hers expects at least $725 million in revenue from its weight-loss services alone in 2025.

In 2023, the company brought in nearly $1.5 billion from more than 2 million customers.

In the fourth quarter of 2023, the company launched an oral weight-loss program, reaching $100 million in revenue in just seven months.

It added GLP-1 drugs like tirzepatide in mid-2024, which brought in about $225 million more that year.

In February, CEO Andrew Dudum said 200,000 new customers joined the platform for weight-loss help over the past year.

Chief Financial Officer Yemi Okupe added, “consumers are very motivated to lose weight and have a holistic platform to do so.”

Sources

  • The Wall Street Journal, April 1, 2025

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted April 2025

Read this next

FDA and Novo Nordisk Alert Consumers to Counterfeit Ozempic

MONDAY, April 21, 2025 -- The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic...

First Weight-Loss Pill From Lilly, Orforglipron, Shows Promising Results

FRIDAY, April 18, 2025 — A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its experimental drug...

Pfizer Ends Testing of Obesity Pill, Danuglipron, After Possible Liver Injury

TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.